Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume

Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial

(2013) Melissa Chrispijn et al.   JOURNAL OF HEPATOLOGY

Diagnosis and management of polycystic liver disease

(2013) Tom J. G. Gevers et al.   Nature Reviews Gastroenterology & Hepatology

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

(2012) M. C. Hogan et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

The long-term outcome of patients with polycystic liver disease treated with lanreotide

(2011) M. Chrispijn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Medical and surgical treatment options for polycystic liver disease1

(2010) Joost P.H. Drenth et al.   HEPATOLOGY

Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease

(2010) M. C. Hogan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases

(2010) Loes Van Keimpema et al.   LIVER INTERNATIONAL

Surgical management and longterm follow-up of non-parasitic hepatic cysts

(2010) Tamara M.H. Gall et al.   HPB

Polycystic Liver Disease

(2009) Thomas Schnelldorfer et al.   ANNALS OF SURGERY

Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled Trial

(2009) Loes van Keimpema et al.   GASTROENTEROLOGY